ArticleCureus2025
An Emerald-Colored Intoxication: A Case of Sulfhemoglobinemia Induced by Metoclopramide.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfhemoglobinemia (SulfHb) is a rare condition characterized by the presence of sulfhemoglobin in the blood, resulting from the incorporation of a sulfur atom into the hemoglobin molecule. This alteration prevents hemoglobin from effectively binding and transporting oxygen, leading to clinical symptoms such as cyanosis and tissue hypoxia. We report the case of a 59-year-old female patient who was admitted to the emergency department for desaturation. The patient presented with persistent lip cyanosis and exertional dyspnea over several months. Blood analyses revealed leukocytosis and the detection of sulfhemoglobin. A diagnosis of SulfHb induced by metoclopramide intoxication was established. The treatment involved discontinuing metoclopramide and administering oxygen. The patient was subsequently monitored monthly during outpatient consultations, and the sulfhemoglobin levels were no longer detectable three months after discharge. This case highlights the synergy between metoclopramide overdose, CYP2D6 inhibition by duloxetine, and exposure to sulfur donors in promoting sulfhemoglobin formation. It underscores the importance of a systematic medication review and the early use of co-oximetry in any unexplained desaturation to avoid diagnostic and management delays. The case underscores the importance of vigilance in prescribing and monitoring pharmacological treatments. Rapid recognition of SulfHb and the utilization of appropriate diagnostic tools are essential to ensure optimal patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.